Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T28124 |
N106
N-106,N 106 |
E1/E2/E3 Enzyme | Ubiquitination |
N106 是 SUMO 激活酶 E1 连接酶的激活剂,并触发 SERCA2a 的内在 sumoylation。 N106 可用于有关心力衰竭的研究。 | |||
T60019 |
VPC-70063
Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)- |
Apoptosis; PARP; c-Myc | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; DNA Damage/DNA Repair |
VPC-70063 (Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-) 是 c-Myc-MAX 的抑制剂。 VPC-70063 的 Myc-Max 转录活性抑制率为 106%,IC50 为 8.9 μM,Myc-Max/UBE2C 下游通路抑制率为 94%。 VPC-70063 可用于抗癌研究。 | |||
T35610 |
2,5-dimethyl Celecoxib
|
Apoptosis; Wnt/beta-catenin; Prostaglandin Receptor | Apoptosis; Cytoskeletal Signaling; GPCR/G Protein; Immunology/Inflammation; Stem Cells |
2,5-dimethyl Celecoxib 是塞来昔布衍生物和微粒体前列腺素 E 合酶 1 (mPGES-1) 的靶向抑制剂,mPGES-1 是炎症介质 PGE2 合成途径中的关键酶。 | |||
T36427 |
PACAP (6-27) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt)
|
PACAP | GPCR/G Protein |
Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells. It binds to PACAP receptors on SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 24.5, 106, and 105 nM, respectively) and inhibits cAMP accumulation induced by PACAP (1-38) (Kis = 457, 102, and 283 nM, respectively, in SH-SY5Y, ... |